A phase I trial of cyclosporine for hospitalized patients with COVID-19

BACKGROUND: COVID-19 remains a global health emergency with limited treatment options, lagging vaccine rates, and inadequate healthcare resources in the face of an ongoing calamity. The disease is characterized by immune dysregulation and cytokine storm. Cyclosporine A (CSA) is a calcineurin inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumberg, Emily A., Noll, Julia Han, Tebas, Pablo, Fraietta, Joseph A., Frank, Ian, Marshall, Amy, Chew, Anne, Veloso, Elizabeth A., Carulli, Alison, Rogal, Walter, Gaymon, Avery L., Schmidt, Aliza H., Barnette, Tiffany, Jurek, Renee, Martins, Rene, Hudson, Briana M., Chavda, Kalyan, Bailey, Christina M., Church, Sarah E., Noorchashm, Hooman, Hwang, Wei-Ting, June, Carl H., Hexner, Elizabeth O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220832/
https://www.ncbi.nlm.nih.gov/pubmed/35536669
http://dx.doi.org/10.1172/jci.insight.155682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220832/
https://www.ncbi.nlm.nih.gov/pubmed/35536669
http://dx.doi.org/10.1172/jci.insight.155682

Ejemplares similares